ICON Public Limited Company
HealthcareNASDAQ:ICLR · NASDAQ Global Select
-$4.14 today
Vol 0.70M · Avg 1.16M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
2.5%
avg 15.7%
ROIC
6.7%
avg 12.5%
ROA
1.4%
avg 8.3%
Analysis
ROIC is currently the strongest return metric at 6.7% versus its period average of 12.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Steve Empoliti | Chief Commercial Officer | $2.51M | — | — | — | — |
Barry Balfe | Chief Executive Officer & Director | $985,000.00 | — | 47 | $4,458.00 | <0.01% |
Nigel Clerkin | Chief Financial Officer | $741,000.00 | — | 52 | $3,855.00 | <0.01% |
John Climax | Founder & Independent Non-Executive Director | $100,000.00 | — | 73 | $5,005.00 | <0.01% |
Lyons Emer | Chief Accounting Officer | — | — | — | $752.00 | <0.01% |
David Green | Vice President of Marketing | — | — | — | — | — |
Diarmaid Cunningham | Chief Administrative Officer, General Counsel & Company Secretary | — | — | 51 | — | — |
Joe Cronin | Chief Human Resources Officer | — | — | — | — | — |
Simon Holmes | President of Corporate Investments & Partnerships | — | — | 59 | — | — |
Thomas N. O'Leary | Chief Information Officer | — | — | — | $0.00 | <0.01% |
Niamh Murphy | Director of Corporate Communications | — | — | — | $5,005.00 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +62.8% | +9.9% (15yr)1 analysts |
| Revenue | N/A | N/A | +12.2% | +12.7% (15yr)5 analysts |
| Net Income | N/A | N/A | +62.9% | +11.9% (15yr)5 analysts |
| EBIT | N/A | N/A | +57.2% | +8.0% (15yr)5 analysts |
Analysis
Recent growth has been strongest in Net Income at +62.9% over three years. Forward estimates point to Revenue at +12.7% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Exact Sciences Corporation
EXAS
$20.03B
Guardant Health, Inc.
NASDAQ:GH
$17.31B
Neurocrine Biosciences, Inc.
NASDAQ:NBIX
$16.15B
Solventum Corporation
NYSE:SOLV
$13.54B
Medpace Holdings, Inc.
NASDAQ:MEDP
$13.40B
The Cooper Companies, Inc.
NASDAQ:COO
$13.22B
Revvity, Inc.
NYSE:RVTY
$11.11B
Encompass Health Corporation
NYSE:EHC
$10.11B
Universal Health Services, Inc.
NYSE:UHS
$9.18B
Qiagen N.V.
NYSE:QGEN
$7.65B
Who manages ICLR?
ICON Public Limited Company (ICLR) lists 11 active executives. The top listed executive is John Climax, Founder & Independent Non-Executive Director.
Are ICLR insiders buying or selling?
Recent insider activity shows net buying of $0.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.